A prospective evaluation of levofloxacin-based triple therapy for refractory Helicobacter pylori infection in Australia

Autor: Arun Maseeh, Peter Katelaris, Anthea Katelaris
Rok vydání: 2017
Předmět:
Zdroj: Internal Medicine Journal. 47:761-766
ISSN: 1444-0903
DOI: 10.1111/imj.13432
Popis: Background First-line Helicobacter pylori eradication failure is a common and challenging problem. Aim To assess the efficacy of salvage levofloxacin-based triple therapy in Australia. Methods Prospective patients referred after prior treatment failure(s) were prescribed esomeprazole 40 mg, amoxicillin 1 g and levofloxacin 500 mg each twice daily for 10 days. All patients received detailed written and verbal adherence support. Outcome assessment was by 13C-urea breath test and/or histology and urease test. Results In 150 consecutive, evaluable patients (66% female, mean age 54 ± 14 years; six smokers), the main indications for treatment were peptic ulcer disease (17%), increased gastric cancer risk (20%), symptoms (35%) and other risk reduction (28%). The median number of previous treatments was 2 (range 1–7). Eradication of H. pylori was achieved in 90% (intention to treat (ITT)) and 91% (per-protocol (PP)) of patients. The eradication rate did not differ according to the type or number of prior treatments: 93% when ≤2 (n = 107) compared with 84% after three or more prior treatments (n = 43; P = 0.13) or with age, ethnicity or indication for treatment but it was higher in females (ITT 94 vs 82%, P = 0.04). Adherence was excellent (95%). No serious adverse effects were observed; mild adverse effects were reported in 11%. No primary levofloxacin resistance was observed in 20 concurrent cases. Conclusion The efficacy and safety of this levofloxacin-based triple therapy suggests it should be used as a salvage regimen in this region. Randomised comparative trials are unlikely to be done but these data compare favourably with local data for other salvage therapies.
Databáze: OpenAIRE
Externí odkaz: